Drug intelligence / Profile preview

compound 20a

Development stage: Preclinical
Modality: Small Molecules

Overview

Compound 20a is a novel small molecule identified as a highly active and selective dual inhibitor of Janus kinase 2 (JAK2) and histone deacetylase 6 (HDAC6). It has demonstrated potent anti-proliferative activity against hematological cell lines and excellent in vivo antitumor efficacy in various acute myeloid leukemia (AML) models. Additionally, compound 20a exhibits synergistic effects with fluconazole in treating resistant Candida albicans infections, highlighting its potential for the combinational treatment of leukemia and invasive fungal infections.

Other names: JAK2/HDAC6 dual inhibitor 20a

Targets

HDAC6 (Histone deacetylase 6)JAK2 (Janus kinase 2)

Beyond the preview

Go deeper on compound 20a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 20a.

Explore the full profile